ANTI-TUMOR NECROSIS FACTOR RECEPTOR (TNFR2) ANTIBODIES AND USES THEREOF

The present disclosure describes a number of anti-TNFR2 (tumor necrosis factor receptor 2) antibodies. These antibodies are TNFR2 agonists. In certain cases, these antibodies agonize TNFR2 in an Fc independent manner. These antibodies can modulate the proliferation and/or functions of regulatory T c...

Full description

Saved in:
Bibliographic Details
Main Authors OFRAN, Yanay, AMIT, Inbar, NIMROD, Guy, GROSSMAN, Noam, FISCHMAN, Sharon, DANIELPUR, Liron, VANA, Tal, OREN, Nino, LEVITIN, Natalia, CHEN, Ayelet, BLUVSHTEIN YERMOLAEV, Olga, ZHENIN, Michael, TWITO, Oshrat Shir, STRAJBL, Marek, DEMISHTEIN, Alik, BARAK FUCHS, Reut, FASTMAN, Yair, BITON, Nevet Zur, SAMET, Dor, WYANT, Timothy, BEN MAYOR, May Sofia, SASSON, Yehezkel, CHOEN ZADA, Efrat, LEVIN, Itay
Format Patent
LanguageEnglish
Published 01.06.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure describes a number of anti-TNFR2 (tumor necrosis factor receptor 2) antibodies. These antibodies are TNFR2 agonists. In certain cases, these antibodies agonize TNFR2 in an Fc independent manner. These antibodies can modulate the proliferation and/or functions of regulatory T cells and myeloid-derived suppressor cells. In certain instances, these antibodies can be used to treat diseases such as GvHD or autoimmune diseases.
Bibliography:Application Number: US202118011251